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ABSTRACT
Objective: Total ceramide concentrations are linked with increased insulin resistance and
cardiac dysfunction. However, recent studies have demonstrated that plasma concentrations
of specific very-long-chain fatty ceramides (C24:0 and C22:0) are associated with a reduced
incidence of coronary heart disease and all-cause mortality. We hypothesized that specific
genetic loci are associated with plasma C22:0 and C24:0 concentrations.
Methods: Heritability and genome-wide association studies of plasma C24:0 and C22:0
ceramide concentrations were performed among 2,217 participants in the Framingham Heart
Study Offspring Cohort, adjusting for cardiovascular risk factor covariates and cardiovascular
drug treatment.
Results: The multivariable-adjusted heritability for C22:0 and C24:0 ceramides was 0.42
(standard error [SE], 0.07; p=1.8E-9) and 0.25 (SE, 0.08; p=0.00025), respectively. Nineteen
single nucleotide polymorphisms (SNPs), all on chromosome 20, significantly associated
with C22:0 concentrations; the closest gene to these variants was SPTLC3. The lead SNP
(rs4814175) significantly associated with 3% lower plasma C22:0 concentrations (p=2.83E-11).
Nine SNPs, all on chromosome 20 and close to SPTLC3, were significantly associated with
C24:0 ceramide concentrations. All 9 were also significantly related to plasma C22:0 levels.
The lead SNP (rs168622) was significantly associated with 10% lower plasma C24:0 ceramide
concentrations (p=9.94E-09).
Conclusion: SNPs near the SPTLC3 gene, which encodes serine palmitoyltransferase long
chain base subunit 3 (SPTLC3; part of the enzyme that catalyzes the rate-limiting step of
de novo sphingolipid synthesis) were associated with plasma C22:0 and C24:0 ceramide
concentrations. These results are biologically plausible and suggest that SPTLC3 may be a
potential therapeutic target for C24:0 and C22:0 ceramide modulation.
Keywords: Genomics; Lipidomics; Cardiovascular disease; Genome-Wide Association Study
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INTRODUCTION
Cardiovascular disease (CVD) is the top cause of death worldwide. Several risk factors for
CVD have been identified, including cholesterol levels, hypertension, and others. However,
even when combined, these known risk factors do not completely predict incident CVD.
Clearly, the identification of novel biomarkers associated with CVD would yield an improved
understanding of disease etiology, aid in the prediction of incident disease, and point toward
new therapeutic targets.
In addition to cholesterol and triglycerides, ceramides are another type of bioactive
lipid species that are of interest as potential markers of CVD risk. The identification of
novel biomarkers associated with these diseases would improve our understanding of
the etiology of CVD, assist in the prediction of incident CVD, and shed light on novel
potential therapeutic targets. Broad inhibition of ceramide synthesis prevents diet- and
glucocorticoid-induced insulin resistance in mice, thus implicating ceramides in the
promotion of metabolic and CVD.1,2 Moreover, in several murine models of metabolic
cardiomyopathy, and in humans, total cardiac ceramide accumulation is associated with
cardiac dysfunction.3-5 Recently, however, studies by our group6 have demonstrated that
plasma levels of specific very-long-chain molecular species of ceramides (C24:0 and C22:0)
are associated with a decreased risk of coronary heart disease (CHD), heart failure (HF), and/
or all-cause mortality. For example, the relative risks of CHD, HF, and all-cause mortality for
each 3-unit increase in plasma C24:0 ceramide levels were 0.79, 0.75, and 0.78, respectively,
even after adjusting for standard CVD risk factors including blood cholesterol. Other groups
have demonstrated that a lower risk of CVD events was associated with increased plasma
C24:0 ceramide and/or C22:0 ceramide concentrations in patients with known CHD.7,8
There is both a de novo and a salvage pathway for sphingolipid and ceramide production,
and specific ceramide synthases create ceramides of specific chain lengths. Both ceramide
synthase 2 and 3 can generate the very-long-chain C22:0 and C24:0 species.9
However, the genomic links between these species are incompletely understood. We hypothesized
that specific loci would be associated with these 2 important complex lipid species. To test this
hypothesis, we leveraged existing genome-wide scans to examine variants associated with C22:0
and C24:0 ceramide concentrations. Our primary aim was to identify variants that met genomewide significance. However, with an exploratory, hypothesis-generating aim, we lowered our
threshold for significance (to p<1E-5) and used pathway analyses to identify which genes had the
strongest potential causal association and would be suitable for further analyses.

MATERIALS AND METHODS
1. Study population
We evaluated clinical, genetic, and metabolomic data from the participants in the
Framingham Heart Study (FHS) Offspring Cohort who took part in the eighth examination
cycle. The FHS samples, inclusion criteria, events, and adjudication have previously been
described.10 We have recently published a paper describing the association of the plasma
C24:0/C16:0 ceramide ratio with clinical outcomes using the same samples.6 Participants
were excluded if they did not have plasma samples available for ceramide concentration
analysis or if their information on covariates (e.g., diabetes status) was missing. Participants
https://e-jla.org
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were also excluded if they did not consent to making their genetic data available for analysis.
A total of 804 subjects who took part in examination after 8 were excluded.

2. Lipidomic analyses
The lipidomic analyses used for these samples have previously been described.6,11 Briefly,
we used a robust, reproducible, and fully validated liquid chromatography/tandem mass
spectrometry assay to quantify C24:0 and C22:0 ceramide levels in frozen plasma samples
from the FHS Offspring Cohort.11 Five percent of the samples were run in duplicate for quality
control. A full description of the lipidomics assay has been presented by Jiang et al.11

3. Genotyping and imputation
Genotyping was conducted using the Affymetrix (Santa Clara, CA, USA) 500K and Affymetrix
50K Supplemental Array. Samples were excluded if they had a call rate <97%, extreme
heterozygosity, or a high Mendelian error rate. Imputation to the 1000 Genomes (August 2010)
reference panel was performed on the data (after appropriate quality control measures) using
MACH version 1.0.16 for SNPs that passed the following criteria: call rate≥97%, probability
of deviation from Hardy-Weinberg equilibrium≥1E-6, mishap p≥1E-9, ≤100 Mendelian errors,
and minor allele frequency (MAF)≥1%. After discarding imputed SNPs with an information
content<0.3, the total number of (genotyped+imputed) SNPs available for analysis was 9,346,801.

4. Statistical analysis
Polygenic heritability
The heritability of continuous C22:0 and C24:0 ceramide concentrations was estimated using
variance component models implemented in SOLAR. The heritability estimation (i.e., the
estimation of the ratio of genetic variance to phenotypic variance) was adjusted for age, sex,
diabetes, smoking status, systolic blood pressure, anti-hypertensive treatment, body mass
index (BMI), and 2 associated principal components (PC1, PC9) of population stratification.

Genome-wide association analysis
Linear mixed-effects models were fitted to relate each genetic variant, assuming an additive
genetic effect model, to continuous C22:0 and C24:0 ceramide concentrations, accounting
for the exact family structure with a kinship coefficient matrix using the lmekin function
in the R coxme package.12 The analyses was adjusted for the same covariates listed above in
the polygenetic heritability section. A p-value of less than 5E-8 was considered to indicate
genome-wide significance.

Pathway analyses
For our secondary, hypothesis-generating aim, DEPICT (v1, https://data.broadinstitute.org/mpg/
depict) was used to prioritize the genes identified from a genome-wide association study (GWAS)
at p<1E-5 with the strongest potential causal association, to identify enriched pathway(s), and to
determine tissues and cell types in which genes from associated loci were highly expressed.

RESULTS
1. Study sample
The baseline characteristics of our study sample are shown in Table 1. The mean age of the
FHS participants in this study was 65.6 (±8.7) years and 45% were men. There was a low
prevalence of smoking and diabetes (9% and 12%, respectively), indicating that this was a
https://e-jla.org
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Table 1. Characteristics of study participants
Variable
FHS (n=2,217)
Min
Max
65.62±8.74
Age (yr)
995 (45)
Male sex (%)
128±17
Systolic blood pressure (mmHg)
27.98±5.10
BMI (kg/m2)
Smokers (%)
209 (9)
Diabetes mellitus (%)
269 (12)
1,013 (46)
Hypertension treatment (%)
3.46±1.06
1.40
11.26
Total to HDL cholesterol ratio
0.60±0.17
0.10
1.53
CER 22:0 (µg/mL)
2.24±0.61
0.30
5.81
CER 24:0 (µg/mL)
Values are mean±standard deviation for continuous variables and number (percentage) for categorical variables.
FHS, Framingham Heart Study; BMI, body mass index; HDL, high-density lipoprotein; CER, ceramide.

generally healthy cohort. Nearly half of the subjects were on antihypertensive medications,
although their blood pressure was well controlled.

2. Heritability
The multivariable-adjusted heritability for C22:0 and C24:0 ceramide levels was 0.42 (standard
error [SE], 0.07; p=1.8E-9) and 0.25 (SE, 0.08; p=0.00025), respectively, after adjustment for
age, sex, diabetes, smoking status, systolic blood pressure, anti-hypertension treatment, BMI,
and 2 associated principal components (PC1, PC9) of population stratification.

3. Genome-wide association analysis
In total, 9,346,801 common variants (MAF>0.05), genotyped or imputed, from 1000
Genomes imputation were tested for associations with plasma C22:0 and C24:0 ceramide
levels in 2,217 FHS subjects after adjustment for confounders. All SNPs (MAF>0.05,
imputation quality>0.3) with association p-values reaching genome-wide significance (<5E-8)
are shown in Table 2 (C22:0 ceramide) and Table 3 (C24:0 ceramide).

Table 2. Top GWAS results for C22:0 ceramide (p<5E-8, MAF>0.05)
SNPID
rsID
Type
Chr
Phys_location Number

β

Distance
to nearest
gene
12959094
2.83E-11
30533
20:12959094
rs4814175
SNP
20
2,217
0.22
−0.031
0.005
SPTLC3
12966089
3.02E-11
23538
20:12966089
rs168622
SNP
20
2,217
0.23
−0.031
0.005
SPTLC3
12962718
3.12E-11
26909
20:12962718
rs364585
SNP
20
2,217
0.23
−0.031
0.005
SPTLC3
12958687
3.47E-11
30940
20:12958687
rs438568
SNP
20
2,217
0.23
−0.031
0.005
SPTLC3
12959885
3.52E-11
29742
20:12959885
rs1321940
SNP
20
2,217
0.23
−0.031
0.005
SPTLC3
12959398
3.56E-11
30229
20:12959398
rs4814176
SNP
20
2,217
0.23
−0.031
0.005
SPTLC3
12969400
3.99E-11
20227
20:12969400
rs680379
SNP
20
2,217
0.22
−0.031
0.005
SPTLC3
12973521
6.76E-11
16106
20:12973521
rs686548
SNP
20
2,217
0.21
−0.031
0.005
SPTLC3
12958492
1.61E-10
31135
20:12958492:A_ACT
NA
Insertion
20
2,217
0.21
−0.031
0.005
SPTLC3
12942649
4.58E-09
46978
20:12942649
rs3848744
SNP
20
2,217
0.21
−0.029
0.005
SPTLC3
12944067
4.66E-09
45560
20:12944067
rs3848745
SNP
20
2,217
0.21
−0.029
0.005
SPTLC3
12945963
4.78E-09
43664
20:12945963
rs3903703
SNP
20
2,217
0.21
−0.029
0.005
SPTLC3
12947532
4.95E-09
42095
20:12947532
rs4814173
SNP
20
2,217
0.21
−0.029
0.005
SPTLC3
12940649
5.14E-09
48978
20:12940649
rs6041735
SNP
20
2,217
0.20
−0.029
0.005
SPTLC3
12950606
5.50E-09
39021
20:12950606
rs3848746
SNP
20
2,217
0.21
−0.029
0.005
SPTLC3
12952964
5.59E-09
36663
20:12952964
rs2327452
SNP
20
2,217
0.21
−0.029
0.005
SPTLC3
12953934
5.73E-09
35693
20:12953934
rs2327451
SNP
20
2,217
0.21
−0.029
0.005
SPTLC3
12943737
5.74E-09
45890
20:12943737
rs3843765
SNP
20
2,217
0.20
−0.029
0.005
SPTLC3
12955601
5.98E-09
34026
20:12955601
rs4508668
SNP
20
2,217
0.21
−0.028
0.005
SPTLC3
GWAS, genome-wide association study; MAF, minor allele frequency; SNP, single-nucleotide polymorphism; Chr, chromosome; SE, standard error; NA, not available.
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Table 3. Top GWAS results for C24:0 ceramide (p<5E-8, MAF>0.05)
SNPID
rsID
Type
Chr
Phys_location

Number

β

variMAF

SE

Distance
to nearest
gene
12966089
0.22985726 −0.100
0.017
23538
20:12966089
rs168622
SNP
20
2,217
9.94E-09
SPTLC3
12962718
0.22783744 −0.100
0.018
26909
20:12962718
rs364585
SNP
20
2,217
1.10E-08
SPTLC3
12969400
0.22385646 −0.101
0.018
20227
20:12969400
rs680379
SNP
20
2,217
1.12E-08
SPTLC3
12959094
0.22384246 −0.101
0.018
30533
20:12959094
rs4814175
SNP
20
2,217
1.14E-08
SPTLC3
12958687
0.2258695
−0.100
0.018
30940
20:12958687
rs438568
SNP
20
2,217
1.32E-08
SPTLC3
12959885
0.22623451 −0.100
0.018
29742
20:12959885
rs1321940
SNP
20
2,217
1.32E-08
SPTLC3
12959398
0.22557234 −0.100
0.018
30229
20:12959398
rs4814176
SNP
20
2,217
1.46E-08
SPTLC3
12973521
0.21422157
−0.102
0.018
16106
20:12973521
rs686548
SNP
20
2,217
1.51E-08
SPTLC3
12958492
0.21169913 −0.101
0.018
31135
20:12958492:A_ACT
NA
Insertion
20
2,217
2.94E-08
SPTLC3
GWAS, genome-wide association study; MAF, minor allele frequency; SNP, single-nucleotide polymorphism; Chr, chromosome; SE, standard error; NA, not available.
p-value

Nearest
gene

The associations of 19 SNPs with plasma C22:0 ceramide concentrations reached genomewide significance (Table 2 and Fig. 1). All 19 SNPs were on a similar region of chromosome 20
and were in strong linkage disequilibrium with each other (Fig. 2). The closest gene to these
variants was SPTLC3, the gene encoding serine palmitoyltransferase long chain base subunit 3
(SPTLC3). The lead SNP (rs4814175) was significantly associated with 3% lower plasma C22:0
ceramide concentrations (p=2.83E-11).
Nine SNPs were significantly associated with plasma C24:0 ceramide concentrations
(Table 3 and Fig. 3). All 9 were on chromosome 20, close to SPTLC3, and in strong linkage
disequilibrium with each other (Fig. 4). The lead SNP (rs168622) was significantly associated
with 10% lower plasma C24:0 ceramide concentrations (p=9.94E-09).
Since for both phenotypes, the variants that reached genome-wide significance were located
in a similar region of chromosome 20 and were in strong linkage disequilibrium with each
10

−log10(p)

8

6

4

2
1

2

3

4

5

6

7

8

9 10

12

14

16 18

21

Coordinate

Chromosom
Chromosom
Fig. 1. Manhattan plot of associations between SNPs and plasma C22:0 ceramide concentrations in 2,217
Framingham Heart Study subjects. SNPs are plotted on the x-axis according to their position on each
chromosome, with the −log10 p-value on the y-axis. The upper dashed horizontal line indicates the threshold for
genome-wide significance, 5×10−8.
SNP, single-nucleotide polymorphism.
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Fig. 2. Regional association and recombination plot for SNPs associated with plasma C22:0 ceramide concentrations. The −log10 p-values for associations with
C22:0 ceramide concentrations are presented on the left y-axis. The chromosome 20 position in megabases (Mb) is presented on the x-axis. The plotted SNPs are
presented in the top panel and the relative positions of genes in the region are presented in the bottom panel. The purple diamond indicates the SNP (rs4814175)
with the most significant association with C22:0 ceramide concentrations. The surrounding SNPs are colored according to their pairwise correlation (r2) with
rs4814175. Estimated recombination hotspots in HapMap (i.e., recombination rates) are represented by blue lines (quantified on the right y-axis).
SNP, single-nucleotide polymorphism.

other, conditional analysis was performed on the lead SNPs to assess the independent
contribution of each SNP. When the analysis was conditioned on the lead SNPs (rs4814175
for C22:0 ceramide and rs168622 for C24:0 ceramide, respectively), the effects of the other
genome-wide significant variants were attenuated, indicating that the 19 SNPs (C22:0
ceramide) and 9 SNPs (C24:0 ceramide) captured the same genetic effect.
Although no other SNPs reached genome-wide significance in the conditional analysis,
a few borderline significant signals emerged: rs191288953 (p=7.41E-08; chromosome 7;
closest gene SDK1) and rs79935880 (p=7.69E-08; chromosome 10; near MTRNR2L7) for
C22:0 ceramide levels and rs34432959 (p=8.68E-08) and rs12963655 (p=8.00E-08) for C24:0
ceramide levels, both of which are located near SYT4 on chromosome 18. The conditional
analysis results of independent SNPs (r2<0.1, MAF>0.05, imputation quality>0.3) with
p-values≤1E-5 for the associations are presented in Supplementary Table 1 for C22:0 ceramide
(n=76) and in Supplementary Table 2 for C24:0 ceramide (n=65) concentrations. To further
assess these variants for biological plausibility, we performed pathway analyses. For plasma
C22:0 ceramide levels, the DEPICT gene prioritization results showed a false discovery rate of
<0.20 for rs79935880 and the enrichment results suggested a false positive rate of <0.20 for

https://e-jla.org
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Fig. 3. Manhattan plot of associations between SNPs and plasma C24:0 ceramide concentrations in 2,217
Framingham Heart Study subjects. SNPs are plotted on the x-axis according to their position on each
chromosome, with the −log10 p-value on the y-axis. The upper dashed horizontal line indicates the threshold for
genome-wide significance, 5×10−8.
SNP, single-nucleotide polymorphism.

ENSG00000138107 and REACTOME_SIGNALING_BY_ROBO_RECEPTOR. No significant
results (false discovery rate<0.20) were identified for plasma C24:0 ceramide levels.

DISCUSSION
Ceramides are complex lipids composed of sphingosine and a fatty acid of varying acyl
chain length. Ceramides have pleiotropic effects. They are found in cell membranes and
can affect cell signaling, apoptosis, differentiation, senescence, and proliferation, as well as
hormonal and stress responses. Studies of ceramides have shown that high total ceramide
concentrations in plasma and/or tissue are related to increased insulin resistance, CVD, and
cardiovascular death in patients with HF.5,13-15 However, higher concentrations of some verylong-chain ceramides in the plasma predict a decreased risk of CHD, HF, and/or all-cause
mortality.6,8 We hypothesized that plasma C22:0 and C24:0 ceramide concentrations would
be heritable and would be associated with genetic variants.
In this study, we demonstrated the heritability of plasma concentrations of C22:0 and C24:0
ceramides. We also showed that 19 SNPs on chromosome 20 were associated with plasma
C22:0 ceramide concentrations and that 9 SNPs on chromosome 20 were associated with
plasma C24:0 ceramide concentrations at a GWAS level of significance (p≤5E-8). The SNPs
were in strong linkage disequilibrium with each other, and when a conditional analysis on
the lead SNP was performed (conditioned on rs4814175 for C22:0 ceramide and rs168622 for
C24:0 ceramide), the effects of the other genome-wide significant variants were attenuated to
non-significance, indicating that the SNPs captured the same genetic effect. All of the SNPs
were within 60 kb of the gene encoding SPTLC3.
https://e-jla.org
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(rs168622) with the most significant association with C22:0 ceramide concentrations. Surrounding SNPs are colored according to their pairwise correlation (r2)
with rs168622. Estimated recombination hotspots in HapMap (i.e., recombination rates) are represented by blue lines (quantified on the right y-axis).
SNP, single-nucleotide polymorphism.

SPTLC3 is a subunit of the enzyme serine palmitoyl transferase (SPT), which catalyzes the
rate-limiting step of de novo synthesis of the sphingoid backbone of sphingolipids, which
are precursors for ceramide synthesis. SPT condenses a fatty acyl-coenzyme A and serine
to create a sphingoid base.16 SPT is composed of 1 or more heterodimers, including the
SPTLC1 subunit, which links the SPT enzyme to the membrane, and a catalytic subunit (e.g.,
SPTLC3 or SPTLC2).16 SPTLC3 is highly expressed in the myocardium.16 The SPTLC3 subunit
enables the SPT enzyme to generate either d16 or d18 sphingoid bases, which are precursors
in ceramide production.16 The specific sphingoid base of the ceramides measured in this
study was 18:1. Different sphingoid base lengths can cause different effects. For example,
d16 bases enhance cell death pathways.16 In addition, different acyl chain lengths appear
to have differential effects on disease pathways. Prior investigators have linked certain
ceramide species (C18:1, C18:0, C20:0, and C24:1 dihydroceramide), with conditions related
to CVD, including diabetes, insulin resistance, and increased plasma levels of inflammatory
mediators, such as tumor necrosis factor alpha.17,18 One small study has also linked C22:0
levels with insulin resistance.17
Genetic polymorphisms in SPTLC3 associated with metabolic phenotypes have also been
previously reported. A recent GWAS investigating 163 metabolic traits revealed that 9 SNPs,
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including the SPTLC rs168622 variant, were associated with the variability of serum levels of
different metabolites and serum metabolite ratios (thought to be representative of enzymatic
reaction rates).19 Specifically, it was found that the SPTLC rs168622 G variant was associated
with higher C24:1 concentrations and lower C24:0/C24:1 concentrations.19 Furthermore,
as mentioned above, higher C24:1 levels have been associated with insulin resistance. It is
challenging to explain exactly how changing 1 subunit (SPTLC3) in a multi-complex enzyme
(SPT) would result in these and other changes in the concentrations of ceramides of different
fatty acyl chain lengths. Changes in SPTLC3 may alter SPT activity or cause compensatory
changes in the expression of other subunits or activity that may lead to different chain
length preferences. In addition, multiple biochemical pathways (e.g., the salvage pathway
in addition to the de novo pathway) lead to ceramide synthesis. Precisely how changing
the efficiency of a single pathway will alter the balance of acyl chains is complex and not
readily predictable, as different pathways may lead to preferences for different acyl chain
incorporation, and there could be changes in the expression or activity of other inputs to
ceramide synthesis. Other investigators have shown that carriers of the SPTLC3 rs168622 GG
variant had lower relative mRNA expression of SPTLC3 and lower total hepatic lipid content.20
Since the SPTLC3 rs168622 GG variant leads to lower mRNA expression of SPTLC3, it is likely
that those individuals have less SPTLC3-mediated generation of d16 (and d18) bases, leading
to lower levels of ceramides composed of d16 bases, which are linked with cell death. Taken
together, these prior observations regarding sphingoid base and/or fatty acyl chain effects
of SPTLC3 SNPs lend biological plausibility to our findings and suggest potential molecular
mechanisms connecting our genomic findings with CVD and its risk factors.
As part of our hypothesis-generating aim, we identified 2 SNPs and 1 pathway that did
not reach genome-wide significance, but had a false discovery rate of less than 20%:
rs79935880 (p=8.05E-7), ENSG00000138107 (p=2.42E-6) and REACTOME_SIGNALING_
BY_ROBO_RECEPTOR (p=2.28E-5). The rs79935880 SNP is a variant of the ANKRD30A gene,
which encodes a transcription factor that is only expressed in breast and testicular tissue.
ENSG00000138107 is located near ACTR1A, which encodes actin related protein 1A, a subunit
of dynactin. REACTOME_SIGNALING_BY_ROBO_RECEPTOR is a set of 30 genes that are
involved in signaling by the Robo receptor; these genes encode transmembrane receptors
that regulate axonal guidance and cell migration and are important in development.
While the biological plausibility of rs79935880 and REACTOME_SIGNALING_BY_ROBO_
RECEPTOR may not be immediately apparent, ENSG00000138107 has obvious potential
biological relevance. Ceramides are signaling molecules that are upregulated in response to
several physiological stressors. The specific effects of these complex lipids appear to relate to
the type of tissue they are in, as well as their acyl chain length.21 Ceramides have a variety of
effects, including pro-apoptosis, pro-mitophagy, pro-survival, and pro-autophagy.22 Specific
ceramide species have been demonstrated to promote programmed cell death through a
cascade of events involving ceramide-mediated channels and a loss of mitochondrial outer
membrane integrity that facilitate the release of cytochrome c and other pro-apoptotic
proteins into the cytoplasm, ultimately resulting in mitophagy and mitochondria-induced
apoptosis.23,24 In contrast, C24:0 ceramide interferes with this process and has predominantly
anti-apoptotic effects.25 Given that dynactin is involved in transport between the endoplasmic
reticulum and Golgi apparatus, as well as the formation and movement of lysosomes
and endosomes, this gene may be an important component of the pathway(s) that are
influenced by C22:0 and C24:0 ceramides, a finding that may provide further insight into the
mechanisms underlying the effects of ceramides.
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Our results validate and extend the findings of previous investigators. Hicks and
colleagues assessed whether a GWAS analysis could identify variants associated with the
concentrations of 33 circulating sphingolipids (24 sphingomyelins and 9 ceramides) in 5
large, presumed to be healthy, European populations.26 The 20p12.1 locus was found to have
the strongest association with serum ceramide concentrations. Although no SNP reached
genome-wide significance in any of the 5 populations, rs680379 reached genome-wide
significance for its associations with both C22:0 and C24:0 ceramide concentrations in a
meta-analysis of all 5 populations. In contrast, when Lemaitre and colleagues27 investigated
whether a GWAS analysis could identify variants associated with the total plasma
phospholipid and erythrocyte levels of 3 saturated, very-long-chain fatty acids (20:0, 22:0,
and 24:0, which included ceramides with these fatty acid acyl chains—C20:0, C22:0, and
C24:0—as well as other lipid moieties) in a meta- analysis of 7 cohorts comprising 10,129
individuals of European ancestry, no genome-wide significant associations were found with
circulating levels of 22:0 or 24:0 fatty acids. However, C20:0 ceramide concentrations were
associated with 7 variants in strong linkage disequilibrium with each other on chromosome
20p12.1; the most significant variant was rs680379.27 Our findings support those of Hicks and
colleagues.26 We also observed that the rs680379 variant reached genome-wide significance
for its associations with both C22:0 and C24:0 ceramide concentrations. Our findings in the
FHS Offspring Cohort provide important validation and confirmation that this locus is an
important genetic determinant of C22:0 and C24:0 ceramide concentrations.
The identification of SNPs that are associated with plasma ceramide concentrations is
important for several reasons. Patients' SPTLC3 genotype status should be considered, and
potentially adjusted for, when assessing plasma ceramide concentrations and determining
individual risk and prognosis. We speculate that in the future, use of genotype-guided,
precision medicine approaches might identify specific patient groups that could benefit from
unique, targeted therapeutic interventions.
Our study should be interpreted in the context of several potential limitations. First, the FHS
Offspring Cohort contains white individuals of European ancestry. Thus, it is unclear whether
these results are generalizable to individuals of different racial or ethnic groups. Second,
our conditional analyses that identified rs79935880, ENSG00000138107, and REACTOME_
SIGNALING_BY_ROBO_RECEPTOR as potentially significant should be considered as
exploratory, as they have not been validated in an independent cohort. However, these
findings, and particularly the association with ACTR1A, are intriguing as they have biological
plausibility and may lead to insights into novel pathways and therapeutics that could benefit
specific populations. In addition, associations (between SNPs related to SPTLC3 and verylong-chain ceramides, as well as between very-long-chain ceramides and CVD) do not prove
causation. Future studies are needed to further investigate the possible causative roles of
genes and specific ceramides for disease. Lastly, the possible effects of the specific SNPs
identified as being significantly related to plasma C22:0 and C24:0 ceramides on other
ceramide species is beyond the scope of this study.
In summary, we have identified SNPs on chromosome 20 associated with plasma C22:0 and
C24:0 ceramide concentrations in individuals from the FHS Offspring Cohort. These SNPs
are near SPTLC3, the gene encoding SPTLC3, which catalyzes the rate-limiting step of de novo
sphingolipid synthesis. Our results are biologically plausible and suggest that SPTLC3 may be
a novel therapeutic target for C24:0 and C22:0 ceramide modulation.
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SUPPLEMENTARY MATERIALS
Supplementary Table 1
Top GWAS results conditional on rs4814175 for C22:0 ceramide concentrations (p≤1E-5,
MAF>0.05)
Click here to view

Supplementary Table 2
Top GWAS results conditional on rs168622 for C24:0 ceramide concentrations (p≤1E-5,
MAF>0.05)
Click here to view
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